Mass Balance Study of ASP1941

Astellas Pharma Inc6 enrolled

Overview

This study investigates the pharmacokinetics, in particular the routes and extent of metabolism and excretion, of ASP1941 after a single oral dose.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Healthy Subjects

Interventions

ASP1941DRUG

Oral solution

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body weight between 60-100kg, BMI between 18.5-30 kg/m2, inclusive Exclusion Criteria: * Pulse \<40 or \>90 bpm; Systolic Blood Pressure \> 140 mmHg; Diastolic Blood Pressure \>90 mmHg

Locations (1)

Unnamed facility

Zuidlaren, Netherlands

Outcomes

Primary Outcomes

Pharmacokinetics of ASP1941 to evaluate metabolism and excretion

Time frame: up to 216 hours

Secondary Outcomes

Identification of metabolic profile of ASP1941

Time frame: up to 216 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.